Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x100px
Organisation › Details

Shinobi Therapeutics Inc.

Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8aß iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. *

 

Period Start 2023-12-12 existent (s-offbef)
  Group Shinobi Therapeutics (Group)
  Today Shinobi Therapeutics (Group)
  Predecessor University of California, San Francisco (UCSF)
Products Industry Katana iPS-T cell therapy paltform (CD8aß iPS-T cell platform)
  Industry 2 off-the-shelf iPS-T cell therapy against GPC3+ cancers (Shinobi Therapeutics)
Person Person Kemp, Daniel M. (Dan) (Shinobi Therapeutics 202312 CEO formerly CEO of Wugen)
     
Region Region South San Francisco, CA
  Country United States (USA)
  City n. a. South San Francisco, CA
    Address record changed: 2023-12-22
     
Basic data Employees n. a.
     
    * Document for »About Section«: Shinobi Therapeutics Inc.. (12/12/23). "Press Release: Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform". San Francisco, CA & Kyoto.
     
   
Record changed: 2024-06-07

Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x200px

More documents for Shinobi Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x300px




» top